History
Bladder cancer, centered on cancer arising from the mucosa (urothelium) lining the inside of the bladder, has long been recorded together with its conspicuous symptom of "blood-tinged urine." In the past, even when visible blood in the urine was present, it was difficult to identify the cause accurately, so tumors were often discovered only after they had grown large. As endoscopic technology advanced from the late 19th century, examinations that directly view the inside of the bladder became possible, and the method of observing tumors with a cystoscope and removing them for biopsy became established. Later, with the standardization of surgical techniques and advances in anesthesia and antibiotics, transurethral resection of bladder tumor (TURBT) came to be widely performed, establishing a "first-line procedure that allows diagnosis and treatment at the same time."
In the mid-20th century, epidemiological studies accumulated showing that smoking and exposure to certain occupational chemicals increase the risk of bladder cancer, and the perspective of prevention was emphasized. At the same time, as it became known that superficial tumors (confined to the mucosa) tend to recur, treatments were developed that instill drugs into the bladder after surgery to reduce recurrence. Most notably, intravesical immunotherapy with Bacillus Calmette–Guérin (BCG) was introduced and became an important treatment for high-risk non-muscle-invasive bladder cancer.
Recently, as imaging and pathological diagnosis have become more refined and molecular biology research has progressed, understanding has deepened of "why some tumors stay shallow while others penetrate the muscle layer and spread." The history of bladder cancer can ultimately be seen as a process that started from a "visible symptom" and improved survival and quality of life as endoscopy, pathology, imaging, and drug therapy were combined step by step.
For muscle-invasive bladder cancer, major surgery to remove the bladder and systemic chemotherapy have become the standard, and new systemic treatments such as immune checkpoint inhibitors have also emerged.
Causes
The most important known cause of bladder cancer is tobacco. Tobacco smoke contains many carcinogens, and after these substances are filtered through the blood by the kidneys, they mix into the urine and repeatedly irritate the bladder mucosa while remaining in the bladder. Therefore, the risk tends to increase with longer smoking duration and greater smoking amount. Quitting smoking reduces the risk over time, but it may not drop completely to zero, so "quitting smoking + immediate testing when symptoms occur" is especially important.
Occupational exposure is also a well-known cause. Aromatic amine chemicals that were once used in certain industries, such as dyes, rubber, leather, printing, and metalworking, are known to increase the risk of bladder cancer. Exposure has now decreased due to workplace safety regulations, but people with a long history of exposure may remain at risk even after a long time has passed. Hair dye is also a well-known causative substance of bladder cancer.
There are also medically related causes. For example, certain anticancer drugs (cyclophosphamide) or radiation therapy to the pelvic area can damage the bladder mucosa and increase the risk of bladder cancer in the long term. Long-term chronic inflammation and irritation are also associated with some types of bladder cancer. Worldwide, there are also known regions where squamous cell carcinoma increases when parasitic infection (schistosomiasis) persists for a long time.
In summary, bladder cancer is a cancer whose risk increases in "situations in which carcinogens excreted in the urine remain in contact with the bladder mucosa for a long time." Factors such as smoking, certain occupational exposures, some drugs and radiation, and long-term inflammation are representative examples.
Genetic Epidemiology
Genetic epidemiology is the perspective that examines "how much genetic differences affect differences in the risk of developing a disease among people." Bladder cancer is generally classified as a cancer strongly influenced by lifestyle and environmental exposures, but genetic factors have also been studied to explain why, even with the same exposure, some people develop cancer and others do not. There are reports that the risk increases somewhat when a family member has bladder cancer, and this may be the result of genetic factors acting together with environmental factors shared by the family.
Genetic differences related to "the process of detoxifying and excreting carcinogens" receive particular attention. Carcinogens contained in tobacco smoke or industrial chemicals are metabolized in the body through several enzymes and excreted in the urine, and depending on variants in the genes involved in this process, carcinogens may remain longer or act more strongly. For example, families involved in detoxification, such as glutathione S-transferase (GST), and families involved in the metabolism of specific chemicals, such as N-acetyltransferase (NAT), have been studied.
It is safest to understand these genetic differences not as "creating a large risk on their own" but as increasing risk when they meet environmental factors such as smoking or occupational exposure. What matters in current clinical practice is not vaguely worrying about one's genetic background, but managing smoking and exposure, which are definite risk factors, and being evaluated quickly when symptoms such as blood in the urine appear.
There is also research suggesting that some rare genetic diseases or differences in DNA repair (damage repair) capacity may be associated with cancer risk, but there are still many limitations before this could be summarized for the general public at the level of "predicting bladder cancer with genetic testing" in everyday life.
General Epidemiology
Bladder cancer is among the relatively common cancers worldwide and occurs especially often in older adults. It is generally diagnosed most often after age 60, and men are diagnosed more often than women. This difference is thought to result from a combination of factors, including smoking rates, patterns of occupational exposure, and hormonal and biological differences.
"Recurrence" is an important feature of bladder cancer. Non-muscle-invasive bladder cancer confined to the bladder mucosa at the time of diagnosis accounts for a considerable proportion of cases, and because it can recur after treatment even in these cases, regular follow-up cystoscopy is considered essential. In contrast, muscle-invasive bladder cancer, which has invaded the muscle layer, carries a greater risk of metastasis, and treatment becomes much more complex.
In terms of histologic type, urothelial carcinoma is the most common. In some regions or situations, other types such as squamous cell carcinoma and adenocarcinoma may be relatively more frequent. In addition, similar urothelial carcinoma can also arise in the upper urinary tract (renal pelvis or ureter), so imaging that also examines the upper urinary tract becomes important in the evaluation of bladder cancer.
Changes in lifestyle and environment also affect incidence. In regions where smoking rates have declined, a tendency for the burden of bladder cancer to decrease over time has been reported, and when workplace safety is strengthened, the risk of certain occupational bladder cancers decreases. In this respect, bladder cancer can also be seen as a cancer in which not only "individual treatment" but also "societal prevention" produces results.
Pathogenesis
Most bladder cancers arise in the course of urothelial cells lining the inside of the bladder repeatedly undergoing damage and recovery over a long period of time. Urine is the pathway through which the body collects and excretes unneeded substances, and in the process, "carcinogens" such as metabolites of tobacco or industrial chemicals can mix into the urine. Because the bladder is the organ that stores urine, these substances remain in contact with the bladder mucosa for a long time. As a result, the DNA of mucosal cells is damaged, and when normal control of cell division breaks down, a tumor can begin.
Two major pathways with different patterns of progression are frequently described for bladder cancer. One is a type that begins as a papillary growth rising from the mucosal surface and tends to remain shallow for a long time while recurring repeatedly. The other is a type that, even without a large protrusion on the surface, has a strong tendency to invade inward through the mucosa, invading the muscle layer relatively early and carrying a greater risk of metastasis. In actual patients, these two pathways can mix and intermediate forms also exist, and ultimately the pathology results (grade, depth of invasion, presence of accompanying carcinoma in situ, etc.) determine the direction of treatment.
The "recurrence" of bladder cancer is also related to the fact that the entire bladder mucosa has been exposed to carcinogens. Even if a tumor is removed from one site, a new tumor can arise again in the mucosa of another site. In summary, the pathogenesis of bladder cancer can be understood as the sequence "carcinogen exposure → mucosal DNA damage → failure of cell regulation → tumor formation and invasion/metastasis," and because the nature of the tumor differs from person to person, pathological classification and risk assessment are important.
In non-muscle-invasive bladder cancer, treatments that instill drugs into the bladder after surgery are also used to eliminate cancer cells that may remain and to change the mucosal environment to reduce recurrence.
Symptoms
The most typical symptom of bladder cancer is painless blood in the urine (hematuria). The urine may look red or brown, and it may appear intermittently, looking normal on some days and then showing blood again. It is easy to ignore it because "blood appeared only once and it is fine now," but bleeding caused by bladder cancer can be erratic like this, so evaluation is needed if visible hematuria has occurred even once.
The second most common symptoms are urinary symptoms that occur when the bladder is irritated. For example, there may be frequent urination (frequency), a sudden urgent need to urinate that is hard to hold (urgency), or a stinging, painful sensation when urinating (dysuria). Because these symptoms are very similar to cystitis, the disease sometimes begins as "cystitis-like symptoms that continue even after taking antibiotics."
As the cancer progresses, the symptoms can become more varied. If a tumor blocks the opening of the ureter, urine backs up toward the kidney, which can cause flank pain or hydronephrosis, and systemic symptoms such as pelvic pain, weight loss, and fatigue can appear. The key symptom of bladder cancer is painless hematuria, and especially when people with risk factors such as older age, a smoking history, or occupational exposure show these symptoms, faster evaluation is needed.
Signs
Signs, unlike the symptoms patients feel themselves, are clues identified through tests or examination. The most commonly observed sign in bladder cancer is hematuria detected on urinalysis. Even when no blood is visible to the naked eye, microscopic hematuria may appear repeatedly, and if it persists even without infection, evaluation of the cause is needed.
On urine cytology, abnormal cells shed into the urine may be found. This can be helpful especially in high-grade tumors or carcinoma in situ (CIS), so it is used as a supplementary test depending on the situation.
The most direct sign is a lesion seen on cystoscopy. When the inside of the bladder is viewed with a cystoscope, papillary protruding tumors, red and rough areas of mucosa, and flat, spreading lesions may be observed. On imaging (computed tomography urography, CTU, or magnetic resonance imaging, MRI), the bladder wall may appear thickened or a mass may be visible, and findings suggesting enlarged lymph nodes or invasion into surrounding organs may be seen.
In advanced cases, systemic findings such as hydronephrosis (in which the ureter is blocked and the upper urinary tract dilates), decreased kidney function, and anemia may accompany the disease. However, because these signs may indicate an already advanced state, "hematuria + a small lesion found on cystoscopy/imaging" is the more common starting point in the early stage.
Screening
Currently, it is difficult to say that a "national screening program recommended for everyone," like those for colorectal cancer or cervical cancer, has been established for bladder cancer. This is because the incidence of bladder cancer is not very high across the whole population, and simple, accurate tests suitable for screening (tests with both high sensitivity and high specificity) are still limited. In addition, if there are many false positives (results that look positive when there is no cancer), invasive tests such as unnecessary cystoscopy may increase.
In practice, evaluation for early detection in "high-risk people" is important. For example, in people with a heavy smoking history, a history of exposure to certain occupational chemicals, or unexplained hematuria, active testing effectively plays the role of screening. The key to screening is not any single test, but connecting people to cystoscopy and imaging at the appropriate time based on risk factors and symptoms (especially hematuria).
The first-line test that can easily be done in general practice is urinalysis. If hematuria recurs on urinalysis, or if hematuria is present and is not due to infection, further evaluation is needed. Urine cytology and urine tumor marker tests can help in some situations, but on their own it is difficult to "feel reassured because the result is normal" or to "confirm cancer because the result is positive."
Diagnosis
The diagnosis of bladder cancer usually begins with an "evaluation of hematuria." First, through history-taking and examination, the physician checks when the hematuria began, how often it occurs, and whether there is pain, and reviews risk factors such as smoking history, occupational exposure, past radiation therapy or anticancer drug use, and recurrent urinary tract infections. Next, urinalysis and urine culture are performed to rule out infection, and urine cytology is performed if needed.
Imaging is important for checking for tumors including the upper urinary tract (kidneys and ureters). Computed tomography urography (CTU) is commonly used, and depending on the situation, ultrasonography (US) or magnetic resonance imaging (MRI) is used as a supplement.
The key to confirming the diagnosis and determining the stage is cystoscopy and biopsy. The lesion is directly confirmed with a cystoscope, and the tumor is resected or a sample is taken by transurethral resection of bladder tumor (TURBT) for pathological examination. These pathology results determine the type of cancer, its grade, and whether it has invaded the muscle layer, and the treatment plan differs greatly accordingly.
If muscle invasion is suspected or there are high-risk findings, additional imaging (CT or MRI of the abdomen, pelvis, and chest, and PET-CT if needed) is performed for staging to evaluate lymph node and distant metastasis. In summary, "suspicion from urinalysis/imaging → confirmation and depth assessment by cystoscopy and TURBT → staging" is the basic flow of diagnosis.
Treatment
Treatment of bladder cancer differs greatly depending on how far into the bladder wall the cancer has invaded. For non-muscle-invasive bladder cancer that is confined to the mucosa or present only in the shallow layers, the basic approach is first to remove the tumor as completely as possible by TURBT. Afterward, if the risk of recurrence is high or carcinoma in situ is present, treatment that instills drugs into the bladder is performed. Most notably, intravesical instillation of BCG (Bacillus Calmette–Guérin) is widely used as a treatment that uses the immune response to reduce recurrence and progression.
For muscle-invasive bladder cancer that has invaded the muscle layer, the goal of treatment moves beyond "local treatment within the bladder" to a stage that also considers the possibility of spread throughout the body. Standard treatment is surgery to remove the bladder (radical cystectomy) with lymph node dissection, and systemic chemotherapy is often given before or after surgery. When the bladder is removed, a new path for urine must be created, and there are several methods, such as attaching a urine bag to the abdomen or using the intestine to create a new bladder that drains through the urethra.
In some patients, treatment that preserves the bladder (bladder-sparing treatment) is also considered. This is an approach in which as much tumor as possible is removed by TURBT, followed by radiation therapy combined with chemotherapy, and it can be chosen when the conditions are suitable.
For advanced bladder cancer that has metastasized or for which surgery is difficult, systemic chemotherapy is central, and recently immunotherapy (immune checkpoint inhibitors) has been used in some patients. Supportive care such as pain control, relief of urinary tract obstruction, and preservation of kidney function is also an important pillar of treatment.
Prognosis
The prognosis of bladder cancer (the course after treatment) depends greatly on the stage and the nature of the tumor. Non-muscle-invasive bladder cancer is confined to the inside of the bladder, so the threat to life is relatively low, but it is characterized by frequent recurrence and the possible need for multiple treatments. Therefore, "having regular cystoscopy even after treatment to detect recurrence early and treat it immediately" determines the prognosis.
Muscle-invasive bladder cancer has penetrated deep into the bladder wall, so the risk of metastasis increases, and because treatment requires major surgery and systemic therapy, the prognosis becomes less favorable. However, with chemotherapy before and after surgery, appropriate staging, skilled surgery, and follow-up care, many patients can expect long-term survival.
When estimating prognosis, the stage (mucosal/muscle invasion/invasion of surrounding organs/metastasis), grade (degree of malignancy of the cells), presence of accompanying carcinoma in situ, presence of lymph node metastasis, and presence of residual tumor after treatment are important. Quality of life after treatment is also an important prognostic factor. When the method of urination changes after bladder removal, a process of adjustment is needed, and even when bladder-sparing treatment is chosen, bladder function and surveillance for recurrence remain important in the long term.
In summary, "for shallow cancer, managing recurrence is key" and "for deep cancer, managing the risk of metastasis is key," and in both cases regular follow-up and lifestyle improvements have a major impact on prognosis.
Prevention
The most clearly effective way to prevent bladder cancer is to quit smoking. Because smoking is one of the greatest risk factors for bladder cancer, not smoking is primary prevention, and if you already smoke, quitting as soon as possible helps lower the risk. Secondhand smoke can also be harmful to health, so reducing tobacco smoke in the living environment is also important.
Preventing occupational exposure is also key. In workplaces that handle certain chemicals, it is necessary to follow safety rules, use protective equipment, and ensure that ventilation and exposure control are properly carried out. People who worked for a long time in related occupations in the past may remain at risk even without current exposure, so if blood in the urine appears, it is important not to dismiss it as "just age" but to be evaluated.
There is a view that adequate fluid intake may help because it can possibly reduce the time carcinogens remain in the bladder. However, because the appropriate amount of fluid intake differs depending on an individual's heart and kidney condition, fluid intake suited to one's health status is preferable to excessive overconsumption. In addition, recurrent urinary tract infections, urinary stones, and chronic inflammation should be appropriately treated and managed.
Practices corresponding to "early detection" are very important in bladder cancer prevention. If visible blood in the urine has occurred even once, getting tested even if the symptom has disappeared is the most realistic and powerful preventive action.